← Evidence map

TrialCardiovascular diabetology2026

Influence of diabetes mellitus on dapagliflozin response after transcatheter aortic valve replacement (TAVR): insights from the DAPA-TAVI trial.

Rocío Párraga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Influence of diabetes mellitus on dapagliflozin response after transcatheter aortic valve replacement (TAVR): insights from the DAPA-TAVI trial. | OpenQuestion